Los Angeles Capital Management’s Kyntra Bio KYNB Stock Holding History

Los Angeles Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-942	Closed	-$873K	–	1601
2020 Q4	$873K	Hold	942	–	–	﹤0.01%	996
2020 Q3	$968K	Hold	942	–	–	﹤0.01%	833
2020 Q2	$955K	Buy	942 +76	+9%	+$70.6K	﹤0.01%	864
2020 Q1	$753K	Buy	+866	New	+$861K	﹤0.01%	784
2019 Q2	–	Sell	-1,254	Closed	-$1.71M	–	1367
2019 Q1	$1.71M	Buy	1,254 +43	+4%	+$58.3K	0.01%	698
2018 Q4	$1.4M	Buy	1,211 +390	+48%	+$438K	0.01%	643
2018 Q3	$1.25M	Sell	821 -161	-16%	-$248K	0.01%	792
2018 Q2	$1.54M	Sell	982 -17	-2%	-$22.2K	0.01%	770
2018 Q1	$1.15M	Buy	+999	New	+$1.32M	0.01%	789
2017 Q4	–	Sell	-208	Closed	-$280K	–	1341
2017 Q3	$280K	Sell	208 -198	-49%	-$209K	﹤0.01%	1167
2017 Q2	$328K	Buy	+406	New	+$283K	﹤0.01%	1046

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Los Angeles Capital Management's KYNB Position: Q1 2021 in Review

Los Angeles Capital Management sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 942 shares — an estimated $873K sold.

Los Angeles Capital Management first reported a position in KYNB in Q2 2017 and held it in 11 quarters. The position peaked at $1.71M in Q1 2019. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

Los Angeles Capital Management reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
Los Angeles Capital Management sold 942 Kyntra Bio shares in Q1 2021, an estimated $873K.
Los Angeles Capital Management first reported a position in Kyntra Bio in Q2 2017 and held it in 11 quarters.
Los Angeles Capital Management's Kyntra Bio position peaked at $1.71M in Q1 2019.
198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Los Angeles Capital Management's 13F filing for Q1 2021, filed 5 May 2021.